IBDEI27A ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,37324,1,3,0)
 ;;=3^Long term (current) use of systmc steroids
 ;;^UTILITY(U,$J,358.3,37324,1,4,0)
 ;;=4^Z79.52
 ;;^UTILITY(U,$J,358.3,37324,2)
 ;;=^5063336
 ;;^UTILITY(U,$J,358.3,37325,0)
 ;;=Z79.1^^140^1787^189
 ;;^UTILITY(U,$J,358.3,37325,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37325,1,3,0)
 ;;=3^Long term (current) use of NSAIDs
 ;;^UTILITY(U,$J,358.3,37325,1,4,0)
 ;;=4^Z79.1
 ;;^UTILITY(U,$J,358.3,37325,2)
 ;;=^5063332
 ;;^UTILITY(U,$J,358.3,37326,0)
 ;;=M30.1^^140^1787^135
 ;;^UTILITY(U,$J,358.3,37326,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37326,1,3,0)
 ;;=3^Eosinophilic Granulomatosis w/ Polyangiitis (EGPA)
 ;;^UTILITY(U,$J,358.3,37326,1,4,0)
 ;;=4^M30.1
 ;;^UTILITY(U,$J,358.3,37326,2)
 ;;=^5011739
 ;;^UTILITY(U,$J,358.3,37327,0)
 ;;=M34.1^^140^1787^89
 ;;^UTILITY(U,$J,358.3,37327,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37327,1,3,0)
 ;;=3^CR(E)ST syndrome
 ;;^UTILITY(U,$J,358.3,37327,1,4,0)
 ;;=4^M34.1
 ;;^UTILITY(U,$J,358.3,37327,2)
 ;;=^5011779
 ;;^UTILITY(U,$J,358.3,37328,0)
 ;;=D89.1^^140^1787^100
 ;;^UTILITY(U,$J,358.3,37328,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37328,1,3,0)
 ;;=3^Cryoglobulinemia
 ;;^UTILITY(U,$J,358.3,37328,1,4,0)
 ;;=4^D89.1
 ;;^UTILITY(U,$J,358.3,37328,2)
 ;;=^29577
 ;;^UTILITY(U,$J,358.3,37329,0)
 ;;=M33.90^^140^1787^101
 ;;^UTILITY(U,$J,358.3,37329,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37329,1,3,0)
 ;;=3^Dermatoplymyostis, unsp, organ invlvmnt, unspec
 ;;^UTILITY(U,$J,358.3,37329,1,4,0)
 ;;=4^M33.90
 ;;^UTILITY(U,$J,358.3,37329,2)
 ;;=^5011774
 ;;^UTILITY(U,$J,358.3,37330,0)
 ;;=L93.0^^140^1787^102
 ;;^UTILITY(U,$J,358.3,37330,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37330,1,3,0)
 ;;=3^Discoid lupus erythematosus
 ;;^UTILITY(U,$J,358.3,37330,1,4,0)
 ;;=4^L93.0
 ;;^UTILITY(U,$J,358.3,37330,2)
 ;;=^5009467
 ;;^UTILITY(U,$J,358.3,37331,0)
 ;;=M1A.20X1^^140^1787^153
 ;;^UTILITY(U,$J,358.3,37331,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37331,1,3,0)
 ;;=3^Gout, chron, drug-inducd, unsp site, w/tophus (tophi)
 ;;^UTILITY(U,$J,358.3,37331,1,4,0)
 ;;=4^M1A.20X1
 ;;^UTILITY(U,$J,358.3,37331,2)
 ;;=^5010926
 ;;^UTILITY(U,$J,358.3,37332,0)
 ;;=M10.9^^140^1787^158
 ;;^UTILITY(U,$J,358.3,37332,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37332,1,3,0)
 ;;=3^Gout, unspecified
 ;;^UTILITY(U,$J,358.3,37332,1,4,0)
 ;;=4^M10.9
 ;;^UTILITY(U,$J,358.3,37332,2)
 ;;=^5010404
 ;;^UTILITY(U,$J,358.3,37333,0)
 ;;=M1A.00X1^^140^1787^154
 ;;^UTILITY(U,$J,358.3,37333,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37333,1,3,0)
 ;;=3^Gout, chron, idiopath, unspec site, w/ tophus (tophi)
 ;;^UTILITY(U,$J,358.3,37333,1,4,0)
 ;;=4^M1A.00X1
 ;;^UTILITY(U,$J,358.3,37333,2)
 ;;=^5010858
 ;;^UTILITY(U,$J,358.3,37334,0)
 ;;=M10.00^^140^1787^157
 ;;^UTILITY(U,$J,358.3,37334,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37334,1,3,0)
 ;;=3^Gout, idiopath, unspec site
 ;;^UTILITY(U,$J,358.3,37334,1,4,0)
 ;;=4^M10.00
 ;;^UTILITY(U,$J,358.3,37334,2)
 ;;=^5010284
 ;;^UTILITY(U,$J,358.3,37335,0)
 ;;=Z00.6^^140^1787^1
 ;;^UTILITY(U,$J,358.3,37335,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37335,1,3,0)
 ;;=3
 ;;^UTILITY(U,$J,358.3,37335,1,4,0)
 ;;=4^Z00.6
 ;;^UTILITY(U,$J,358.3,37335,2)
 ;;=^5062608
 ;;^UTILITY(U,$J,358.3,37336,0)
 ;;=Z00.6^^140^1787^134
 ;;^UTILITY(U,$J,358.3,37336,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,37336,1,3,0)
 ;;=3^Encntr for exam for nrml cmprsn & ctrl in clin rsrch prog
 ;;^UTILITY(U,$J,358.3,37336,1,4,0)
 ;;=4^Z00.6
 ;;^UTILITY(U,$J,358.3,37336,2)
 ;;=^5062608
 ;;^UTILITY(U,$J,358.3,37337,0)
 ;;=M79.7^^140^1787^136
